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Efficacy and Safety of Ixekizumab in the Treatment of 
Radiographic Axial Spondyloarthritis: Sixteen- Week 
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Response to or Intolerance of Tumor Necrosis Factor 
Inhibitors
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Pentti Järvinen,7 Juan Sanchez-Burson,8 Karl Gaffney,9 Eun Bong Lee,10 Eswar Krishnan,11 Silvia Santisteban,11 
Xiaoqi Li,11 Fangyi Zhao,11 Hilde Carlier,11 and John D. Reveille,12 for the COAST-W Study Group
Objective. To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spon-
dyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi).
Methods. In this phase III randomized, double- blind, placebo- controlled trial, adult patients with an inadequate 
response to or intolerance of 1 or 2 TNFi and an established diagnosis of axial SpA (according to the Assessment of 
SpondyloArthritis international Society [ASAS] criteria for radiographic axial SpA, with radiographic sacroiliitis defined 
according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive 
placebo or 80- mg subcutaneous ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W), with an 80- mg or 160- 
mg starting dose. The primary end point was 40% improvement in disease activity according to the ASAS criteria 
(ASAS40) at week 16. Secondary outcomes and safety were also assessed.
Results. A total of 316 patients were randomized to receive placebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n = 114). At 
week 16, significantly higher proportions of IXEQ2W patients (n = 30 [30.6%]; P = 0.003) or IXEQ4W patients (n = 29 [25.4%]; 
P = 0.017) had achieved an ASAS40 response versus the placebo group (n = 13 [12.5%]), with statistically significant 
differences reported as early as week 1 with ixekizumab treatment. Statistically significant improvements in disease 
activity, function, quality of life, and spinal magnetic resonance imaging–evident inflammation were observed after 16 
weeks of ixekizumab treatment versus placebo. Treatment- emergent adverse events (AEs) with ixekizumab treatment 
were more frequent than with placebo. Serious AEs were similar across treatment arms. One death was reported (IX-
EQ2W group).
Conclusion. Ixekizumab treatment for 16 weeks in patients with active radiographic axial SpA and previous inad-
equate response to or intolerance of 1 or 2 TNFi yields rapid and significant improvements in the signs and symptoms 
of radiographic axial SpA versus placebo.
ClinicalTrials.gov identifier: NCT02696798.
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INTRODUCTION
Axial spondyloarthritis (SpA) is a chronic inflammatory dis-
ease that is estimated to affect 0.9–1.4% of adults in the US and 
encompasses both nonradiographic axial SpA and radiographic 
axial SpA (1,2). Radiographic axial SpA is also referred to as anky-
losing spondylitis (AS). The disease is typically characterized by 
inflammatory back pain and radiographically defined sacroiliac 
(SI) joint structural damage (2,3). Patients with axial SpA may also 
exhibit peripheral musculoskeletal (inflammatory arthritis, enthesi-
tis, and dactylitis) and extraarticular (uveitis, psoriasis, and inflam-
matory bowel disease [IBD]) involvement.
Currently, the American College of Rheumatology/Spondyli-
tis Association of America/Spondyloarthritis Research and Treat-
ment Network, the Assessment of SpondyloArthritis international 
Society (ASAS)/European League Against Rheumatism, and the 
National Institute for Health and Care Excellence guidelines for 
the management of axial SpA recommend treatment with tumor 
necrosis factor inhibitors (TNFi) in patients with axial SpA who 
do not respond or tolerate nonsteroidal antiinflammatory drugs 
(NSAIDs) (4–6). Approximately 30–40% of patients with AS do not 
achieve adequate disease control or symptom relief according to 
clinical trials of TNFi (7–12). In addition, some patients may not be 
eligible to receive TNFi due to relative contraindications (13).
The interleukin- 17 (IL- 17) axis has been linked to the immu-
nopathology of axial SpA (14,15). IL- 17 inhibition has demon-
strated efficacy in patients with AS; however, an IL- 17 antagonist 
has not been evaluated in a population that exclusively consisted 
of patients with prior inadequate response to or intolerance of 
TNFi in a clinical trial setting (16). This is an important population 
on which to focus, given that it has been shown to be difficult to 
treat, with treatment responses lower in magnitude than observed 
in biologics- naive populations (17,18).
Ixekizumab is a high- affinity monoclonal antibody that selec-
tively targets IL- 17A (19). Here we present the 16- week results of 
COAST- W, a phase III clinical trial investigating the efficacy and 
safety of ixekizumab in patients with active radiographic axial SpA 
and previous inadequate response to or intolerance of 1 or 2 TNFi.
PATIENTS AND METHODS
Trial design. COAST- W is a multicenter, phase III, ran-
domized, double- blind, placebo- controlled, parallel-group, outpa-
tient clinical trial of 1 year’s duration, followed by an optional 2- year 
extension trial (COAST- Y) (see Supplementary Figure 1, available 
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40753/abstract). Patient enrollment 
and data collection occurred at 106 sites located in 15 countries 
across North America, South America, Europe, and Asia (for a 
list of investigators and sites, see Supplementary Appendix A, 
available at http://onlinelibrary.wiley.com/doi/10.1002/art.40753/
abstract). This trial was conducted in accordance with the eth-
ical principles of the Declaration of Helsinki and in compliance 
with local laws and regulations. All participants provided informed 
consent. COAST- W protocol and consent forms were approved 
by each site’s institutional review board or ethics committee. The 
trial was registered with ClinicalTrials.gov (NCT02696798) and the 
European Union Clinical Trials Register (2015- 003937- 84).
Trial participants. Complete inclusion and exclusion cri-
teria are provided in Supplementary Appendix B (available at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40753/abstract). 
Eligible subjects were age ≥18 years, required to have an estab-
lished diagnosis of axial SpA and fulfillment of ASAS classification 
criteria for radiographic axial SpA (i.e., radiographic evidence of 
sacroiliitis according to the modified New York criteria and having 
≥1 SpA feature), and required to have a history of back pain for ≥3 
months with an age at onset of <45 years (20–22). SI joint radio-
graphs were scored by central readers. All patients fulfilling ASAS 
criteria for radiographic axial SpA (20) also fulfilled the modified 
New York criteria for AS (21).
Additional inclusion criteria included a baseline Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI) score (23) of ≥4, 
a baseline total back pain numeric rating scale score of ≥4, and a 
history of therapy for axial SpA of at least 12 weeks’ duration prior 
to screening. Patients were required to have discontinued at least 
1 TNFi, but no more than 2 TNFi, either due to intolerance or due 
to an inadequate response (in the opinion of the investigator) to 
treatment with a single TNFi for at least 12 weeks at an adequate 
dose. The required TNFi washout periods are described in Sup-
plementary Appendix B and were based upon the half- lives of the 
respective TNFi.
The exclusion criteria included total spinal ankylosis 
(according to the site investigator’s opinion), active or recent 
infections, current or history of lymphoproliferative or malig-
nant disease (<5 years prior to baseline) or other medical con-
ditions (e.g., systemic inflammatory diseases or chronic pain 
conditions such as fibromyalgia), other non- TNF biologic or 
other immunomodulatory agent treatments, or surgical proce-
dures that could pose an unacceptable risk to patients or that 
could confound interpretation of trial results. Patients with IBD 
(Crohn’s disease or ulcerative colitis) were eligible if no disease 
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exacerbations had occurred for ≥6 months (stable treatment 
allowed). Patients with anterior uveitis were eligible if no exac-
erbations had occurred for ≥4 weeks.
Patients could continue to receive the following medications 
at a stable dose: sulfasalazine (≤3 gm/day), methotrexate (≤25 
mg/week), prednisone or equivalent (≤10 mg/day), and NSAIDs. 
No changes to these medications were allowed during the blinded 
treatment dosing period, except for safety reasons. Analgesics 
were also allowed according to the eligibility criteria (see Supple-
mentary Appendix B, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40753/abstract).
Randomization and blinding. Patients were randomly 
assigned (1:1:1) to receive subcutaneous administration of ixeki-
zumab 80 mg every 2 weeks (IXEQ2W group), ixekizumab 80 mg 
every 4 weeks (IXEQ4W group), or matched placebo from week 0 
to week 16. Patients randomized to the ixekizumab treatment reg-
imens were randomized (1:1) to receive either an 80- mg or 160- 
mg starting dose of ixekizumab at week 0. The 2 starting doses 
were included in order to assess the impact of starting dose on 
week 16 responses, following regulatory agency feedback. All 
patients received the same frequency and number of injections 
regardless of treatment arm or assigned starting dose.
During the double- blinded treatment period (weeks 0–16), 
site personnel, patients, and the sponsor trial team were 
blinded with regard to treatment. Randomization to treatment 
groups was determined using a computer- generated, random- 
sequence, interactive web- response system with follow- up con-
firmation by site personnel using the confirmation number pres-
ent on the investigational product packaging. Randomization of 
treatment assignment (including starting dose) was stratified by 
country, high- sensitivity C- reactive protein (CRP) level (≤5 or >5 
mg/liter) at screening, and the number of prior TNFi taken (1 or 
2) to achieve between- group comparability.
At week 16, patients entered the extended treatment period 
(weeks 16–52). Patients who were initially assigned to the placebo 
arm were, for the extended treatment period, randomly reassigned 
at week 16 to IXEQ4W or IXEQ2W with a 160- mg starting dose. 
Patients already receiving ixekizumab remained on their assigned 
treatment regimens through week 52.
Procedures of product administration. The investiga-
tional product was supplied in prefilled manual syringes for subcu-
taneous administration, with trial- specific labels. Ixekizumab and its 
matching placebo were visually indistinguishable from each other. 
To maintain blinding, all patients received 2 injections at week 0 
and 1 injection every 2 weeks. Placebo patients received a pla-
cebo injection every 2 weeks and IXEQ4W patients received a pla-
cebo injection every other 2 weeks to maintain blinding. Patients 
assigned to an ixekizumab treatment regimen received their start-
ing dose (either 80- mg ixekizumab [1 80- mg injection and 1 pla-
cebo injection] or ixekizumab 160 mg [2 80- mg injections]) at week 
0. Trial visits and data collection occurred at baseline (week 0) and 
at weeks 1, 2, 4, 8, 12, and 16 during the blinded treatment dosing 
period. The primary end point was assessed at week 16.
Efficacy and safety assessments. The primary end 
point of the trial was the proportion of patients achieving an 
ASAS 40% improvement in disease activity (ASAS40) (22) at 
week 16, with comparison of each ixekizumab dosing regimen 
to placebo. Major secondary end points assessed at week 16 
were ASAS20, an Ankylosing Spondylitis Disease Activity Score 
(ASDAS) of <2.1 (inactive or low disease activity) (24), and 
changes from baseline in the ASDAS, BASDAI, Bath Ankylos-
ing Spondylitis Functional Index (BASFI) (25), Medical Outcomes 
Study Short Form 36 (SF- 36) health survey physical component 
score (PCS) (26), ASAS Health Index (ASAS- HI) (27,28), and 
Spondyloarthritis Research Consortium of Canada (SPARCC) 
magnetic resonance imaging (MRI) index for the spine (MRI pro-
tocol addendum only) (29). These end points were assessed at 
every visit (i.e., screening, baseline, weeks 1, 2, 4, 8, 12, and 16) 
except for the SF- 36 PCS and ASAS- HI (collected at baseline, 
weeks 4, 8, and 16) and MRI (collected at baseline and week 
16). Additionally, CRP level was assessed at every visit. All listed 
end points are described in Supplementary Appendix C, avail-
able on the Arthritis & Rheumatology web site at http://onlineli-
brary.wiley.com/doi/10.1002/art.40753/abstract.
Safety outcomes were assessed at every visit. Data on terms 
related to cerebrocardiovascular events and suspected IBD were 
adjudicated by external clinical event committees. Details on adju-
dication criteria are provided in Supplementary Appendix C.
Statistical analysis. The sample size of COAST- W was 
estimated to have 96% power for testing the superiority of IXEQ2W 
to placebo for an ASAS40 response at week 16 (for details on 
power analysis assumptions, see Supplementary Appendix C).
Efficacy analyses for the blinded treatment dosing period 
included all randomized patients according to the treatment to 
which they were assigned. Analyses of the IXEQ2W and IXEQ4W 
treatment groups were performed without regard to the starting 
dose. Missing values (including for those patients who discon-
tinued trial treatment) were imputed as nonresponders using 
nonresponder imputation for categorical variables; continuous 
variables were analyzed using a mixed- effects model of repeated 
measures (MMRM) without imputation for missing values.
The primary analysis method for categorical outcome vari-
ables was logistic regression with treatment, geographic region, 
baseline CRP status (≤5 versus >5 mg/liter), and the number of 
prior TNFi taken included in the model. Secondary analysis of cat-
egorical outcomes was performed using Fisher’s exact test when 
the logistic model did not converge due to sparse data.
The primary analysis method for continuous outcomes, 
except SPARCC MRI index scores, was MMRM with treatment, 
geographic region, baseline CRP level, the number of prior TNFi 
DEODHAR ET AL 602       |
taken, baseline value, visit, baseline value–by- visit, and treatment- 
by- visit interaction as fixed factors. The primary analysis method 
for SPARCC MRI index scores was analysis of covariance 
(ANCOVA) with observed case analysis, with inclusion only of 
patients with both baseline (between 42 days prior to and 14 days 
after the first injection) and week 16 (injection date at week 16 
[±14 days]) SPARCC MRI index scores. The ANCOVA included 
treatment, geographic region, baseline CRP level, number of prior 
TNFi taken, and baseline value.
A graphical multiple testing strategy was implemented for pri-
mary and major secondary objectives to control the overall family- 
wise Type I error rate at a 2- sided alpha level of 0.05 (see Sup-
plementary Figures 2–4, available on the Arthritis & Rheumatology 
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40753/
abstract). There was no adjustment for multiple comparisons for 
any other analyses. The analyses investigating efficacy prior to 
week 16 were not included in the multiple testing strategy.
Descriptive analyses (with no prespecified hypothesis test-
ing) were performed using the safety population, which was 
defined as all randomized patients who received ≥1 dose of the 
trial drug, according to assigned treatments. Safety data were 
summarized as the frequency of events occurring in each treat-
ment group during the blinded treatment dosing period.
RESULTS
Patient disposition and baseline characteristics. 
The Consolidated Standards of Reporting Trials  (CONSORT) 
diagram is provided in Figure 1. Of the 610 patients assessed 
for trial eligibility, 316 were randomly assigned to either pla-
cebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n =114), and 
294 patients were designated as ineligible at screening or 
were discontinued prior to randomization. The predominant 
reason for ineligibility at screening was the lack of definitive 
sacroiliitis according to centrally read SI joint radiographs (n = 
217 [35.6%]) (see Supplementary Table 1, available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40753/abstract). The 
number of patients screened and enrolled for each country 
is shown in Supplementary Table 2 (available at http://online 
library.wiley.com/doi/10.1002/art.40753/abstract). The 16- week  
blinded treatment dosing period was completed by 93 patients 
(89.4%) receiving placebo, 90 patients (91.8%) receiving 
IXEQ2W, and 99 patients (86.8%) receiving IXEQ4W. Overall, 
282 patients (89.2%) completed week 16.
Treatment arms were generally balanced for baseline demo-
graphic and clinical characteristics (Table 1). Baseline spondyloar-
thritis features are listed in Supplementary Table 3 (available at 
Figure 1. Disposition of the patients. Details are given according to the Consolidated Standards of Reporting Trials (CONSORT) statement 
for reporting randomized controlled trials.
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Table 1. Patient demographic and clinical characteristics for the intent- to- treat population in the COAST- W study*
Placebo group 
(n = 104)
IXEQ2W group 
(n = 98)
IXEQ4W group 
(n = 114)
Age, mean ± SD years 46.6 ± 12.7 44.2 ± 10.8 47.4 ± 13.4
Male sex 87 (83.7) 75 (76.5) 91 (79.8)
Race
White 85 (81.7) 78 (79.6) 91 (80.5)
Asian 13 (12.5) 13 (13.3) 14 (12.4)
Weight, mean ± SD kg 84.3 ± 17.9 79.3 ± 17.3 85.5 ± 20.2
<70 kg 21 (20.2) 25 (25.5) 24 (21.1)
≥70 kg 83 (79.8) 73 (74.5) 90 (78.9)
Body mass index, mean ± SD kg/m2 28.9 ± 5.6 27.5 ± 5.4 29.4 ± 7.3
Age at onset of axial SpA, mean ± SD years 27.1 ± 8.8 28.1 ± 10 28.9 ± 9.6
Duration of symptoms since axial SpA onset, 
mean ± SD years
19.9 ± 11.6 16.5 ± 9.6 18.8 ± 11.6
Duration of disease since axial SpA diagnosis, 
mean ± SD years
13.0 ± 10.5 11.7 ± 8.8 10.1 ± 7.8
Use of DMARDs 
Methotrexate 20 (19.2) 9 (9.2) 12 (10.5)
Sulfasalazine 13 (12.5) 16 (16.3) 17 (14.9)
Use of oral corticosteroid 14 (13.5) 11 (11.2) 11 (9.6)
Use of NSAIDs 84 (80.8) 71 (72.4) 86 (75.4)
Prior TNFi experience†
1 prior TNFi 62 (59.6) 66 (68.0) 70 (61.4)
2 prior TNFi 42 (40.4) 31 (32.0) 44 (38.6)
Reason for failing prior TNFi‡
Inadequate response to 1 TNFi 64 (61.5) 66 (68.0) 75 (65.8)
Inadequate response to 2 TNFi 32 (30.8) 20 (20.6) 26 (22.8)
Intolerance of TNFi 8 (7.7) 11 (11.3) 13 (11.4)
TNFi washout period, median  
(minimum–maximum) days§
123.5 
(31.0–4,053.0)
143.0 
(32.0–3,851.0)
153.5 
(29.0–4,639.0)
Baseline C- reactive protein, mean ± SD mg/liter 16.0 ± 22.3 16.9 ± 19.8 20.2 ± 34.3
≤5.00 mg/liter 39 (37.5) 26 (26.5) 44 (38.6)
>5.00 mg/liter 65 (62.6) 72 (73.5) 70 (61.4)
ASDAS, mean ± SD 4.1 ± 0.8 4.2 ± 0.8 4.2 ± 0.9
BASDAI score, mean ± SD 7.3 ± 1.3 7.5 ± 1.3 7.5 ± 1.3
BASFI score, mean ± SD 7.0 ± 1.7 7.4 ± 1.4 7.4 ± 1.8
ASAS- HI score, mean ± SD 9.0 ± 3.5 10.1 ± 3.6 10.0 ± 3.7
SF- 36 PCS, mean ± SD 30.6 ± 7.8 27.9 ± 7.3 27.5 ± 8.3
SPARCC MRI spine score, mean ± SD¶ 6.4 ± 10.2 11.1 ± 20.3 8.3 ± 16
SPARCC MRI spine score ≥2¶ 25 (49.0) 24 (45.3) 31 (53.4)
* Except where indicated otherwise, values are the number (%) of patients in the analysis population. IXEQ2W = 80- mg subcuta-
neous  ixekizumab every 2 weeks; IXEQ4W = 80- mg subcutaneous ixekizumab every 4 weeks; SpA = spondyloarthritis; DMARDs = 
disease- modifying antirheumatic drugs; NSAIDs = nonsteroidal antiinflammatory drugs; ASDAS = Ankylosing Spondylitis Dis-
ease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional 
Index; ASAS- HI = Assessment of Spondyloarthritis international Society Health Index; SF- 36 = Medical Outcomes Study Short 
Form 36 health survey; PCS = physical component score; SPARCC = Spondyloarthritis Research Consortium of Canada. 
† Patients were included regardless of whether they were inadequate responders to or intolerant of tumor necrosis factor 
inhibitors (TNFi). 
‡ If a patient had both an inadequate response to 1 TNFi and an intolerance of another TNFi, that patient was classified as having 
had an inadequate response to 1 TNFi. Patients in the intolerance category discontinued prior TNFi (1 or 2) due to intolerance only. 
§ Washout period for the last TNFi taken. Data were available for all but 1 IXEQ2W patient. 
¶ Data were available for the magnetic resonance imaging (MRI) addendum population only (n = 51 for the placebo group, 
n = 58 for the IXEQ2W group, and n = 53 for the IXEQ4W group). 
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http://onlinelibrary.wiley.com/doi/10.1002/art.40753/abstract). 
Overall, 315 patients had prior TNFi experience; 205 patients 
(65.1%) had an inadequate response to 1 TNFi, 78 patients 
(24.8%) had an inadequate response to 2 TNFi, and 32 patients 
(10.2%) were intolerant of TNFi. One patient was inadvertently 
enrolled without prior TNFi experience. Reasons for the discontin-
uation of previous biologic therapies are provided in Supplemen-
tary Table 4 (available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40753/abstract). The median washout period for TNFi prior 
to study entry was 5 months (minimum 1 month, maximum 155 
months). At baseline, 86 patients (27.2%) were receiving concomi-
tant conventional synthetic disease- modifying antirheumatic drugs 
(DMARDs; sulfasalazine or methotrexate).
Clinical end points. Ixekizumab was found to be superior 
to placebo for the primary and all major secondary end points 
at week 16 with both ixekizumab treatment regimens, except for 
ASAS- HI scores with IXEQ2W (Figures 2–4 and Supplementary 
Table 5, available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40753/abstract). The proportion of patients who achieved the 
primary end point of an ASAS40 response at week 16 was signif-
icantly higher among patients treated with either IXEQ2W (n = 30 
[30.6%]; P = 0.003) or IXEQ4W (n = 29 [25.4%]; P = 0.017) than 
among patients treated with placebo (n = 13 [12.5%]), with a sig-
nificant response observed as early as week 1 for both ixekizumab 
regimens (Figure 2A). The proportion of patients who achieved an 
ASAS20 response at week 16 was also significantly higher among 
patients treated with either IXEQ2W (n = 46 [46.9%]) or IXEQ4W 
(n = 55 [48.2%]) than among patients treated with placebo (n = 31 
[29.8%]), with a significant response as early as week 1 for both 
dosing regimens (Figure 2B). The starting dose of 160 mg versus 
80 mg at week 0 did not lead to a significant improvement of the 
results observed at week 16 (Supplementary Figure 5, available 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40753/abstract). 
Further analyses are required in order to evaluate the effect of 
starting dose on speed of onset.
Statistically significant improvements in measures of disease 
activity were observed among patients treated with IXEQ2W or 
IXEQ4W relative to placebo at week 16, as measured by a change 
from baseline in ASDAS and BASDAI scores, as well as achieve-
Figure  2. Proportion of patients achieving A, 40% improvement in disease activity according to the Assessment of SpondyloArthritis 
international Society criteria (ASAS40) or B, ASAS20 responses through week 16 when treated with placebo (PBO), ixekizumab every 2 weeks 
(IXEQ2W), or ixekizumab every 4 weeks (IXEQ4W). * = P < 0.05; † = P < 0.01; ‡ = P < 0.001, all versus placebo by logistic regression analysis, 
except for week 1 with ASAS40, for which Fisher’s exact test was used due to model nonconvergence. Only analyses at week 16 were included 
in the prespecified multiple testing strategy. n = number of patients in the analysis category; N = number of patients in the analysis population.
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ment of ASDAS <2.1 (inactive or low disease activity) (Figures 3A–C). 
Patient function was also significantly improved at week 16 in 
patients treated with IXEQ2W or IXEQ4W relative to placebo, as 
mea sured by a change from baseline in BASFI scores (Figure 3D).
Quality of life end points. Statistically significant 
improvements in quality of life, as measured by mean change 
from baseline in the SF- 36 PCS, were reported at week 16 
for patients treated with IXEQ2W and IXEQ4W versus placebo 
 (Figure  3E). Similarly, statistically significant improvements in 
health  functioning, as measured by mean change from baseline 
in ASAS- HI scores, were reported at week 16 among patients 
treated with IXEQ4W versus placebo (Figure 3F).
Spinal MRI and systemic inflammation. Spinal MRI 
and systemic inflammation significantly improved in patients 
treated with IXEQ2W or IXEQ4W, as demonstrated by the mean 
change from baseline in SPARCC MRI index spine scores and in 
mean change from serum baseline CRP levels, respectively, at 
week 16 versus placebo (Figures 4A and B).
Safety. Safety outcomes reported in COAST- W during 
the blinded treatment dosing period are summarized in Table 2. 
Overall mean ± SD exposure was 109.1 ± 19.6 days or a total 
of 94.4 patient- years. The proportions of patients in each ixeki-
zumab treatment regimen who reported treatment- emergent 
adverse events (TEAEs) were higher than those for placebo 
patients and were similar between ixekizumab treatment regi-
mens. Most reported TEAEs were mild or moderate in sever-
ity. Severe TEAEs occurred in 7 placebo patients (6.7%), 4 
IXEQ2W patients (4.1%), and 4 IXEQ4W patients (3.5%). The 
most frequently reported TEAEs (occurring in ≥5% of patients 
receiving ixekizumab overall) were upper respiratory tract infec-
tions and injection site reactions. AEs leading to discontinuation 
Figure 3. Major secondary outcomes investigating disease activity, function, and quality of life among patients treated with placebo (PBO), 
ixekizumab every 2 weeks (IXEQ2W), or ixekizumab every 4 weeks (IXEQ4W) for 16 weeks. A–D, Ankylosing Spondylitis Disease Activity 
Score (ASDAS) (A), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (B), ASDAS score <2.1 (C), and  Bath Ankylosing Spondylitis 
Functional Index (BASFI) (D). E and F, Medical Outcomes Study Short Form 36 (SF- 36) health survey, physical component score (PCS) (E) and 
Assessment of Spondyloarthritis international Society Health Index (ASAS- HI) (F). * = P < 0.05; † = P < 0.01; ‡ = P < 0.001, all versus placebo 
by mixed- effects model of repeated measures (MMRM) or logistic regression analysis (C only). Only analyses at week 16 were included in the 
prespecified multiple testing strategy. Values shown at week 16 for all measures (except C) are the least squares mean (LSM) ± SE.
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were reported for 2 placebo patients (1.9%), 3 IXEQ2W patients 
(3.1%), and 10 IXEQ4W patients (8.8%) (for specific AEs, see 
Supplementary Table 6, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40753/abstract). Few serious AEs were reported, with similar 
rates across treatment arms: n = 5 (4.8%) for placebo patients, 
n = 3 (3.1%) for IXEQ2W patients, and n = 4 (3.5%) for IXEQ4W 
patients. One death (suicide) occurred in the IXEQ2W treatment 
arm, in a patient with a documented prior history of depression 
of ~1 year (reported as mild at study entry), and was judged by 
the blinded principal investigator to be unrelated to the investi-
gational product.
The incidence of infections was higher for ixekizumab than 
for placebo, with most infections being mild or moderate (Table 2). 
Two Candida infections were reported in the IXEQ2W study arm 
(1 esophageal and 1 genital candidiasis), 1 herpes zoster infection 
was reported in the IXEQ4W study arm, and no infections were 
reported in the placebo group. Serious infections were reported 
in 2 patients in the IXEQ4W group (1 peritonitis and 1 pharyngitis; 
both patients continued the trial). No new cases of tuberculosis or 
reactivation were reported during the trial.
Reported injection site reactions were all mild or moderate in 
severity, occurred across all treatment arms (n = 6 [5.8%] for pla-
cebo, n = 16 [16.3%] for IXEQ2W, and n = 9 [7.9%] for IXEQ4W), 
and led to treatment discontinuation in only 2 patients (1 each in 
the IXEQ2W and IXEQ4W groups).
Mild neutropenia (grade 1) occurred more frequently in the 
ixekizumab arms than in the placebo arm, was transient in nature, 
and resolved spontaneously while ixekizumab treatment continued. 
A single case of grade 2 neutropenia was reported in each ixeki-
zumab treatment arm; 1 of these cases existed before treatment 
began. One malignancy (acute promyelocytic leukemia [PML]) was 
reported 4 weeks postbaseline in the IXEQ4W treatment arm. The 
single report of grade 4 neutropenia was in this same patient. A 
post hoc analysis of a serum sample collected prior to investiga-
tional product exposure revealed that this patient had a genetic risk 
factor for acute PML (PML/retinoic acid receptor ɑ mutation) prior 
to trial entry. Treatment was discontinued in this patient.
Figure 4. Spondyloarthritis Research Consortium of Canada (SPARCC) magnetic resonance imaging (MRI) index spine scores (A) and serum 
C- reactive protein (CRP) levels (B) among patients treated with placebo (PBO), ixekizumab every 2 weeks (IXEQ2W), or ixekizumab every 4 
weeks (IXEQ4W) through 16 weeks. † = P < 0.01; ‡ = P < 0.001, all versus placebo by analysis of covariance (ANCOVA) and least squares 
mean (LSM) (A) or mixed- effects model of repeated measures (MMRM) and LSM (B). Only SPARCC MRI spine score analyses at week 16 were 
included in the prespecified multiple testing strategy. Values shown are the LSM ± SE. N = number of patients in the analysis population; Nx = 
number of patients in the MRI addendum population.
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Single adjudicated cerebrocardiovascular events were 
reported in the placebo and IXEQ2W treatment arms. The cer-
ebrocardiovascular events were confirmed as stent placement 
(placebo group) and atrial fibrillation (IXEQ2W group), respectively. 
Both of these patients continued treatment through week 16. No 
major adverse cerebrocardiovascular events were reported dur-
Table 2. Adverse events (AEs) and treatment- emergent adverse events (TEAEs) during the 16- week blinded 
treatment dosing period of the COAST- W study*
Placebo 
group 
(n = 104)
IXEQ2W 
group 
(n = 98)
IXEQ4W 
group 
(n = 114)
TEAE 51 (49.0) 59 (60.2) 73 (64.0)
Mild 18 (17.3) 23 (23.5) 34 (29.8)
Moderate 26 (25.0) 32 (32.7) 35 (30.7)
Severe 7 (6.7) 4 (4.1) 4 (3.5)
Discontinuation due to AE 2 (1.9) 3 (3.1) 10 (8.8)
Serious AE 5 (4.8) 3 (3.1) 4 (3.5)
Death 0 1 (1.0) 0
Common TEAEs†
Upper respiratory tract infection 3 (2.9) 4 (4.1) 9 (7.9)
Injection site reaction 1 (1.0) 8 (8.2) 3 (2.6)
TEAEs of special interest
Hepatic 2 (1.9) 1 (1.0) 5 (4.4)
Cytopenia 0 2 (2.0) 0
Grade 1 neutropenia (≥1.5 to <2.0 × 109 cells/liter) 1 (1.0) 8 (8.2) 10 (8.8)
Grade 2 neutropenia (≥1.0 to <1.5 × 109 cells/liter) 0 1 (1.0) 1 (0.9)
Grade 3 neutropenia (≥0.5 to <1.0 × 109 cells/liter) 0 0 0
Grade 4 neutropenia (<0.5 × 109 cells/liter) 0 0 1 (0.9)
Infections 10 (9.6) 23 (23.5) 34 (29.8)
Mild 5 (4.8) 14 (14.3) 20 (17.5)
Moderate 5 (4.8) 9 (9.2) 13 (11.4)
Severe 0 0 1 (0.9)
Serious 0 0 2 (1.8)
Candida (genital) 0 1 (1.0) 0
Candida (esophageal) 0 1 (1.0) 0
Herpes zoster 0 0 1 (0.9)
Reactivated tuberculosis 0 0 0
Allergic reactions/hypersensitivities 1 (1.0) 6 (6.1) 3 (2.6)
Potential anaphylaxis 0 0 0
Injection site reactions‡ 6 (5.8) 16 (16.3) 9 (7.9)
Cerebrocardiovascular events§ 1 (1.0) 1 (1.0) 0
Malignancies 0 0 1 (0.9)
Depression 5 (4.8) 2 (2.0) 0
Anterior uveitis¶ 0 3 (3.1) 2 (1.8)
Inflammatory bowel disease 1 (1.0) 0 3 (2.6)
Interstitial lung disease 0 0 0
* Values are the number (%) of patients in the analysis population. IXEQ2W = 80- mg subcutaneous ixekizumab 
every 2 weeks; IXEQ4W = 80- mg subcutaneous ixekizumab every 4 weeks. 
† Common TEAEs are defined as those that occurred at a frequency of ≥5% for patients receiving ixekizumab 
(both treatment regimen populations combined). 
‡ Injection site reaction high- level terms include injection site, pain, erythema, dermatitis, hypersensitivity, pru-
ritus, bruising, rash, and paresthesia or reaction (unspecified). 
§ Confirmed cerebrocardiovascular events only. 
¶ Anterior uveitis was not a prespecified AE of special interest but was included in the prespecified analyses. 
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ing the blinded treatment dosing period. Depression was reported 
more often in patients taking placebo (n = 5 [4.8%]) than in patients 
taking IXEQ2W (n = 2 [2.0%]) and IXEQ4W (n = 0).
IBD was reported in 1 patient (1.0%) in the placebo arm 
(colitis), no patients in the IXEQ2W arm, and in 3 patients (2.6%) 
in the IXEQ4W arm (1 colitis, 1 ulcerative colitis, and 1 Crohn’s 
 disease). Two cases (1 in the placebo group and 1 in the IXEQ4W 
group) were flares in patients with a preexisting diagnosis of IBD. 
Of the other 2 IBD cases (IXEQ4W group), 1 case was in a cur-
rent smoker (smoking since 1994) with a perianal cyst reported in 
2010 and accompanying intermittent abdominal pain since that 
time. The other case was in a long- term smoker (since 2009), 
who stopped smoking 3 months prior to trial entry, with a prior 
history of anemia (2012–2014) and intermittent diarrhea since 
2011 (ongoing but mild at time of trial entry). All reported cases 
of IBD were adjudicated as “probable.” Anterior uveitis was 
reported  in 3 IXEQ2W patients (3.1%) and 2 IXEQ4W patients 
(1.8%); 3 of these 5 patients (2 in the IXEQ2W group and 1 in the 
IXEQ4W group) were documented to have a preexisting history 
of anterior uveitis; 4 of the 5 patients were HLA–B27 positive, 
and all had longstanding disease (experiencing symptoms for 
at least 7 years and up to 28 years). Psoriasis was reported in 
2 patients with a previous medical history of psoriasis (1 in the 
placebo group and 1 in the IXEQ4W group).
Treatment- emergent antidrug antibodies were observed 
in 3 placebo patients (2.9%), 4 IXEQ2W patients (4.1%), and 
8 IXEQ4W patients (7.1%). Most of the reported antidrug anti-
bodies were classified as being low titer, 2 IXEQ2W patients 
(2.0%) and 1 IXEQ4W patient (0.9%) were reported as having 
moderate titers, and 1 IXEQ2W patient (0.9%) was reported 
with high titers. Neutralizing antidrug antibodies were detected 
in 3 IXEQ4W patients (2.7%). No associations were identified 
between treatment- emergent antidrug antibody status and 
ASAS40 response, injection site reactions, or potential allergic/
hypersensitivity events with either ixekizumab treatment regimen.
DISCUSSION
The COAST- W trial is the first large, randomized, controlled 
trial focusing exclusively on radiographic axial SpA patients 
with prior treatment failure (inadequate response to or intoler-
ance of 1 or 2 TNFi). In that respect, this study differs from other 
reported phase III studies of radiographic axial SpA that enrolled 
exclusively or predominantly biologic DMARD (bDMARD)–naive 
patients. Ixekizumab was superior to placebo in reducing the 
signs and symptoms of radiographic axial SpA in this popula-
tion of patients with longstanding disease and very high disease 
activity. For the primary end point (ASAS40 response), both 
IXEQ2W and IXEQ4W were superior to placebo at week 16. 
Statistically significant and clinically meaningful improvements 
over placebo were also observed at week 16 for all major sec-
ondary end points, including measures of disease activity, func-
tion, and quality of life for IXEQ4W and for all but 1 (ASAS- HI) 
major secondary end points for IXEQ2W. Statistically significant 
improvements over placebo were reported early in the trial for all 
of these end points. In addition, and despite baseline levels of 
spinal inflammation being relatively low, thereby hampering the 
ability to show improvement, a statistically significant and objec-
tive effect on spinal inflammation was observed for IXEQ2W and 
IXEQ4W, as measured by the SPARCC MRI index score, which 
was supported by parallel improvements in CRP levels. The spi-
nal MRI data are the first to be reported in a large subset of 
patients with prior intolerance of or inadequate response to TNFi 
in the context of a placebo- controlled registration study.
Despite the greater exposure with the IXEQ2W regimen, 
IXEQ2W did not show a clinically meaningful incremental increase 
in observed efficacy relative to the IXEQ4W regimen. Similarly, the 
week 0 starting dose of ixekizumab 160 mg did not reveal a clin-
ically meaningful incremental improvement in week 16 response 
rates relative to the 80- mg starting dose for either ixekizumab 
regimen. The impact of starting dose on speed of onset requires 
further analysis.
Ixekizumab showed an acceptable safety profile in this 
patient population with longstanding and very active disease. 
The frequency of TEAEs in this population (patients with prior 
inadequate response to or intolerance of TNFi) was higher across 
all treatment arms, including placebo, than those reported in a 
bDMARD- naive population with radiographic axial SpA from 
another phase III ixekizumab study (COAST- V, NCT02696785) 
(30). TEAEs occurred more often with ixekizumab than with pla-
cebo, mostly driven by upper respiratory tract infections and 
injection site reactions. Serious AEs occurred at similar rates 
across ixekizumab and placebo treatment arms. The reported 
frequencies for total TEAEs and serious AEs are consistent with 
those reported among patients with psoriasis and psoriatic 
arthritis (PsA) treated with ixekizumab (31–34). Discontinuations 
due to AEs were similar for IXEQ2W relative to placebo but higher 
for IXEQ4W relative to placebo, with no particular AE driving the 
difference. The explanation for this discrepancy is unclear, given 
that there were no discontinuations due to AEs in the IXEQ4W 
treatment arm in the study of ixekizumab treatment in bDMARD- 
naive patients with radiographic axial SpA (30).
Infection frequencies were higher in patients treated with 
ixekizumab relative to placebo. The majority of infections were 
mild, with the most commonly reported being upper respiratory 
tract infections and nasopharyngitis. Serious infections were 
uncommon (n = 2). Reported infection frequencies were higher 
than those reported in COAST- V, but consistent with or lower than 
those reported in trials of ixekizumab for PsA and psoriasis (30).
Injection site reactions (high- level terms) were higher in 
patients treated with ixekizumab relative to placebo, and similar 
to or lower than previously observed in trials of ixekizumab for 
PsA and psoriasis (33,34). One case of grade 4 neutropenia was 
reported in the IXEQ4W treatment arm in a patient with treatment- 
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emergent acute PML who had a genetic risk factor for this dis-
ease. In the IXEQ2W treatment arm, one patient with a docu-
mented prior history of depression committed suicide, which was 
judged by the blinded investigator to be unrelated to the investi-
gational product.
The incidences of IBD and acute anterior uveitis in the cur-
rent study involving patients with prior inadequate response to 
or intolerance of 1 or 2 TNFi, and longstanding (mean ± SD 
 symptom duration 18.4 ± 11.1 years) and very active disease, 
were higher than reported among bDMARD- naive patients with 
radiographic axial SpA treated with ixekizumab (30). Certain 
comorbidities in axial SpA, especially IBD and acute anterior 
uveitis, have been reported to be associated with longer dis-
ease duration (35). Integrated data from the ixekizumab axial 
SpA studies, as well as longer- term data, are needed to bet-
ter understand whether the IBD events observed in the current 
study reflect the recruited patient population, study treatment, 
other factors (such as discontinuation of prior TNFi), or a combi-
nation of the above (36).
The incidence of ixekizumab antidrug antibodies was low 
and consistent with previous reports in patients with PsA and 
prior inadequate response to or intolerance of 1 or 2 TNFi (34). 
Ixekizumab antidrug antibodies were not associated with immune 
reactions or reductions in efficacy.
TNFi and 1 IL- 17A antagonist (secukinumab) are the only 
approved biologic agents for treatment of AS. The ixekizumab 
results reported here for patients with inadequate response to 
or intolerance of 1 or 2 TNFi are consistent with those previously 
reported for secukinumab in patients with inadequate response 
to or intolerance of 1 TNFi (subset of 85 patients from the 
MEA SURE- 2 study) (18). However, given that other baseline 
characteristics may also differ between these 2 studies, direct 
comparisons should not be made between the trial results. Both 
MEASURE- 2 and COAST- W demonstrate that IL- 17A antago-
nists are efficacious and well- tolerated in patients with prior intol-
erance of or inadequate response to TNFi.
The COAST- W trial has several strengths. It is the first large, 
randomized, controlled trial to focus exclusively on patients with 
radiographic axial SpA with a prior inadequate response to or 
intolerance of 1 or 2 TNFi. This focus allowed for a comprehensive 
evaluation of the baseline characteristics, burden of disease, and 
treatment efficacy and safety in this population. COAST- W also 
used the ASAS40 response as the primary end point, reflecting 
major improvement and representing a more stringent end point 
than the commonly used ASAS20. In addition, COAST- W is the 
first placebo- controlled trial to generate spinal MRI data in a TNFi- 
intolerant or inadequate responder population. Conversely, the 
current data set is limited to a 16- week treatment period. Longer- 
term data, which are being collected through 1 year of treatment 
in the present trial, as well as during an optional 2- year extension 
trial, will provide further information on the long- term efficacy and 
safety of ixekizumab.
In conclusion, the findings of this study demonstrate that 
the ixekizumab treatment regimens yield rapid and significant 
improvements in the signs and symptoms of radiographic axial 
SpA, as well as a significant reduction in inflammation of the spine 
as measured by MRI, when compared to placebo. The current 
results support ixekizumab as a treatment option for patients with 
radiographic axial SpA and prior inadequate response to or intol-
erance of TNFi.
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